DPP-IV Inhibitors to Account for 17% of the Indian Oral Antidiabetics Market by 2015

July 01, 2011
Top Quote Driven by a rich pipeline and a strong safety-efficacy profile, the market for DPP-IV inhibitors in India is expected to reach more than US$ 163 Million in the next five years. This would represent around 17% of the total oral antidiabetics market by 2015. End Quote
  • (1888PressRelease) July 01, 2011 - According to IMARC's new research report "India Diabetes Market Report & Outlook for 2010-2015", DPP-IV Inhibitors are expected to account for 17% of the total oral antidiabetics market by 2015. According to the research, there are currently three players operating in this market. MSD was the first to enter the market with its two drugs Januvia (Sitagliptin) and Janumet (Sitagliptin+Metformin), and represents the current market leader. The other two Players are Novartis and local manufacturer USV. Both players have tied up to market Galvus (Vidagliptin) and Eucreas (Vidagliptin+Metformin) in the Indian market.

    The research thoroughly investigates the factors which will drive the growth of DPP-IV inhibitors and other oral antidiabetic drugs in India. Analysts from IMARC believe that despite the fact that DPP-IV inhibitors are more expensive than conventional oral antidiabetic drugs such as Biguanides and Sulphonylureas, there is still a significant patient population that can afford high priced innovative drugs in India. According to IMARC, the high safety-efficacy profile associated with DPP-IV Inhibitors, coupled with their rich pipeline will be a key factor in driving the growth of this market in the next five years.

    Findings from the research suggest that apart from the four products already available, three new DPP-IV Inhibitors will be launched in India in the next five years. IMARC expects the DPP-IV Inhibitor market to reach sales worth more than US$ 163 Million by 2015.

    "Indian Diabetes Market Report and Outlook for 2010-2015" gives a deep insight into the Indian diabetes market. The research study serves as an analytical as well as a statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in India. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Indian diabetes market in some form or the other.

    Table of Contents

    1. EXECUTIVE SUMMARY
    2. DIABETES DISEASE OVERVIEW
    2.1 WHAT IS DIABETES?
    2.2 DIABETES DIAGNOSIS AND TREATMENT
    2.2.1 Diagnosis
    2.2.2 Treatment
    2.3 DIABETES COMPLICATIONS
    3. WHY IS THE DIABETES MARKET SO LUCRATIVE IN INDIA
    3.1 INDIA HAS THE LARGEST DIABETIC POPULATION IN THE WORLD.
    3.2 INDIA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
    3.3 IMPROVING DIAGNOSIS AND TREATMENT RATES
    3.4 LARGE UNTAPPED MARKET
    3.5 BRIGHT OUTLOOK FOR INNOVATIVE DRUGS
    4. THE INDIAN DIABETES EPIDEMIOLOGY
    4.1 TOTAL PREVALENCE
    4.1.1 Type1 & Type2 Prevalence
    4.1.2 Urban and Rural Prevalence
    4.1.3 Prevalence of Diabetes by Sex
    4.1.4 Prevalence of Diabetes by Age Group
    4.1.5 Prevalence of Diabetes in Various Regions in India
    4.2 DIAGNOSIS AND TREATMENT RATES IN INDIA
    5. THE INDIAN DIABETES MARKET
    5.1 MARKET TREND (2005-2009)
    5.2 MARKET SEGMENTATION (2005-2009)
    5.3 MARKET FORECASTS (2010-2015)
    6. THE INDIAN NON-INSULIN ANTI-DIABETICS MARKET
    6.1 MARKET TREND (2005-2009)
    6.2 COMPETITIVE LANDSCAPE (2005-2009)
    6.3 MARKET FORECASTS (2010-2015)
    6.4 MARKET SEGMENTATION (2005-2015)
    6.4.1 Glitazones
    6.4.1.1 Market Trend (2005-2009)
    6.4.1.2 Competitive Landscape
    6.4.1.2.1 Share of Key Players
    6.4.1.2.2 Portfolio of Key Players
    6.4.1.3 Market Forecasts (2010-2015)
    6.4.2 Biguanides
    6.4.2.1 Market Trend (2005-2009)
    6.4.2.2 Competitive Landscape
    6.4.2.2.1 Share of Key Players
    6.4.2.2.2 Portfolio of Key Players
    6.4.2.3 Market Forecasts (2010-2015)
    6.4.3 Sulphonylureas
    6.4.3.1 Market Trend (2005-2009)
    6.4.3.2 Competitive Landscape
    6.4.3.2.1 Share of Key Players
    6.4.3.2.2 Portfolio of Key Players
    6.4.3.3 Market Forecasts (2010-2015)
    6.4.4 Alpha-Glycosidase Inhibitors
    6.4.4.1 Market Trend (2005-2009)
    6.4.4.2 Competitive Landscape
    6.4.4.2.1 Share of Key Players
    6.4.4.2.2 Portfolio of Key Players
    6.4.4.3 Market Forecasts (2010-2015)
    6.4.5 Dpp-IV Inhibitors
    6.4.5.1 Market Trend (2008-2009)
    6.4.5.2 Competitive Landscape
    6.4.5.2.1 Share of Key Players
    6.4.5.2.2 Portfolio of Key Players
    6.4.5.3 Market Forecasts (2010-2015)
    6.4.6 Glinides
    6.4.6.1 Market Trend (2005-2009)
    6.4.6.2 Competitive Landscape
    6.4.6.2.1 Share of Key Players
    6.4.6.2.2 Portfolio of Key Players
    6.4.6.3 Market Forecasts (2010-2015)
    6.4.7 Glp-1 Agonists
    6.4.7.1 Market Trend (2008-2009)
    6.4.7.2 Competitive Landscape
    6.4.7.2.1 Share of Key Players
    6.4.7.2.2 Portfolio of Key Players
    6.4.7.3 Market Forecasts (2010-2015)
    6.4.8 All other Classes
    6.4.8.1 Market Trend (2005-2009)
    6.4.8.2 Competitive Landscape
    6.4.8.2.1 Share of Key Players
    6.4.8.2.2 Portfolio of Key Players
    6.4.8.3 Market Forecasts (2010-2015)
    7. THE INDIAN INSULIN MARKET
    7.1 MARKET TREND (2005-2009)
    7.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
    7.3 MARKET SEGMENTATION BY MODE OF ACTION
    7.4 COMPETITIVE LANDSCAPE
    7.4.1 Share of key Players
    7.4.2 Portfolio of Key Players
    7.5 MARKET FORECASTS (2010-2015)
    8. ROAD BLOCKS
    8.1 LOW AVERAGE PER PATIENT SPENDING ON DIABETES DRUGS
    8.2 PREFERENCE FOR INEXPENSIVE AND OLDER DRUG CLASSES
    8.3 HIGHLY FRAGMENTED AND 'GENERICIZED' MARKET
    8.4 LOW RATES OF DRUG TREATED POPULATION IN RURAL AREAS

    To buy the complete report or to get a free sample:

    Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)

    email: sales ( @ ) imarcgroup dot com
    For more Information please visit: http://www.imarcgroup.com/

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information
  • Krishna Sharma
  • Imarc Group
  • 21/601 Eastend Apartment Mayur Vihar Phase-1 Extention Delhi-110096, India
  • 201301
  • Voice: 91-11-43095788
  • Visit our Site
Over Satisfied Users & Approved Press Releases
© Copyright 2005-2024, 1888 Press Release. All Rights Reserved